SELLAS Life Sciences (SLS) Non-Current Deferred Tax Liability (2015 - 2021)

SELLAS Life Sciences (SLS) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $152000.0 the latest figure, recorded in Q4 2021.

• In Q4 2021, Non-Current Deferred Tax Liability fell 89.03% year-over-year to $152000.0; the TTM figure through Dec 2021 stood at $152000.0 (down 89.03% YoY), while the FY2021 annual figure was $152000.0, down 89.03% from the prior year.
• Non-Current Deferred Tax Liability eased to $152000.0 in Q4 2021 per SLS's latest filing, from $239000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.7 million in Q1 2017 and bottomed at $152000.0 in Q4 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $1.5 million across 5 years, with a median of $357000.0 in 2018.
• Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability slumped 89.62% — and 2020, when it surged 428.63%.
• SELLAS Life Sciences' Non-Current Deferred Tax Liability stood at $3.4 million in 2017, then plunged by 89.62% to $357000.0 in 2018, then slipped by 26.61% to $262000.0 in 2019, then soared by 428.63% to $1.4 million in 2020, then sank by 89.03% to $152000.0 in 2021.
• Business Quant data shows SLS's Non-Current Deferred Tax Liability at $152000.0 in Q4 2021, $239000.0 in Q3 2021, and $239000.0 in Q2 2021.